ALX Oncology Holdings Analyst Ratings
ALX Oncology Holdings Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/14/2023 | 16.96% | Stifel | $11 → $10 | Maintains | Buy |
10/11/2023 | 28.65% | Piper Sandler | $8 → $11 | Maintains | Overweight |
10/04/2023 | 215.79% | UBS | $29 → $27 | Maintains | Buy |
10/04/2023 | 169.01% | Cantor Fitzgerald | $18 → $23 | Maintains | Overweight |
10/03/2023 | 104.68% | HC Wainwright & Co. | $16 → $17.5 | Reiterates | Buy → Buy |
09/12/2023 | 110.53% | Cantor Fitzgerald | → $18 | Reiterates | Overweight → Overweight |
09/07/2023 | 110.53% | Cantor Fitzgerald | → $18 | Reinstates | Overweight → Overweight |
08/14/2023 | 110.53% | Cantor Fitzgerald | $22 → $18 | Maintains | Overweight |
08/11/2023 | 110.53% | Cantor Fitzgerald | $22 → $18 | Maintains | Overweight |
08/11/2023 | -6.43% | Piper Sandler | $48 → $8 | Maintains | Overweight |
08/11/2023 | 87.13% | HC Wainwright & Co. | $30 → $16 | Maintains | Buy |
07/24/2023 | 157.31% | Cantor Fitzgerald | → $22 | Reiterates | Overweight → Overweight |
05/12/2023 | 250.88% | HC Wainwright & Co. | → $30 | Reiterates | Buy → Buy |
03/15/2023 | 239.18% | UBS | $31 → $29 | Maintains | Buy |
03/10/2023 | 297.66% | Credit Suisse | $38 → $34 | Maintains | Outperform |
03/10/2023 | 250.88% | HC Wainwright & Co. | $65 → $30 | Maintains | Buy |
11/09/2022 | 660.23% | HC Wainwright & Co. | $80 → $65 | Maintains | Buy |
08/09/2022 | 344.44% | Credit Suisse | $43 → $38 | Maintains | Outperform |
06/06/2022 | 87.13% | Stifel | $35 → $16 | Maintains | Buy |
05/19/2022 | 461.4% | Piper Sandler | $70 → $48 | Maintains | Overweight |
03/01/2022 | 321.05% | Stifel | $60 → $36 | Maintains | Buy |
12/22/2021 | 192.4% | Jefferies | $65 → $25 | Downgrades | Buy → Hold |
09/30/2021 | 1139.77% | Stifel | → $106 | Initiates Coverage On | → Buy |
04/06/2021 | 1022.81% | UBS | → $96 | Initiates Coverage On | → Buy |
02/11/2021 | 1046.2% | Credit Suisse | $62 → $98 | Maintains | Outperform |
02/10/2021 | 1069.59% | HC Wainwright & Co. | → $100 | Initiates Coverage On | → Buy |
08/11/2020 | 648.54% | Cantor Fitzgerald | → $64 | Initiates Coverage On | → Overweight |
08/11/2020 | 543.27% | Piper Sandler | → $55 | Initiates Coverage On | → Overweight |
08/11/2020 | 484.8% | Jefferies | → $50 | Initiates Coverage On | → Buy |
08/11/2020 | 519.88% | Credit Suisse | → $53 | Initiates Coverage On | → Outperform |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
11/14/2023 | 16.96% | Stifel | 11 美元 → 10 美元 | 维持 | 购买 |
2023 年 11 月 10 日 | 28.65% | 派珀·桑德勒 | 8 美元 → 11 美元 | 维持 | 超重 |
2023 年 4 月 10 日 | 215.79% | 瑞银(UBS) | 29 美元 → 27 美元 | 维持 | 购买 |
2023 年 4 月 10 日 | 169.01% | 坎托·菲茨杰拉德 | 18 美元 → 23 美元 | 维持 | 超重 |
2023 年 3 月 10 日 | 104.68% | HC Wainwright & Co. | 16 美元 → 17.5 美元 | 重申 | 购买 → 购买 |
09/12/2023 | 110.53% | 坎托·菲茨杰拉德 | → 18 美元 | 重申 | 超重 → 超重 |
09/07/2023 | 110.53% | 坎托·菲茨杰拉德 | → 18 美元 | 恢复 | 超重 → 超重 |
08/14/2023 | 110.53% | 坎托·菲茨杰拉德 | 22 美元 → 18 美元 | 维持 | 超重 |
08/11/2023 | 110.53% | 坎托·菲茨杰拉德 | 22 美元 → 18 美元 | 维持 | 超重 |
08/11/2023 | -6.43% | 派珀·桑德勒 | 48 美元 → 8 美元 | 维持 | 超重 |
08/11/2023 | 87.13% | HC Wainwright & Co. | 30 美元 → 16 美元 | 维持 | 购买 |
2023 年 7 月 24 日 | 157.31% | 坎托·菲茨杰拉德 | → 22 美元 | 重申 | 超重 → 超重 |
05/12/2023 | 250.88% | HC Wainwright & Co. | → 30 美元 | 重申 | 购买 → 购买 |
03/15/2023 | 239.18% | 瑞银(UBS) | 31 美元 → 29 美元 | 维持 | 购买 |
03/10/2023 | 297.66% | 瑞士信贷 | 38 美元 → 34 美元 | 维持 | 跑赢大盘 |
03/10/2023 | 250.88% | HC Wainwright & Co. | 65 美元 → 30 美元 | 维持 | 购买 |
11/09/2022 | 660.23% | HC Wainwright & Co. | 80 美元 → 65 美元 | 维持 | 购买 |
08/09/2022 | 344.44% | 瑞士信贷 | 43 美元 → 38 美元 | 维持 | 跑赢大盘 |
2022 年 6 月 6 日 | 87.13% | Stifel | 35 美元 → 16 美元 | 维持 | 购买 |
05/19/2022 | 461.4% | 派珀·桑德勒 | 70 美元 → 48 美元 | 维持 | 超重 |
03/01/2022 | 321.05% | Stifel | 60 美元 → 36 美元 | 维持 | 购买 |
12/22/2021 | 192.4% | 杰富瑞集团 | 65 美元 → 25 美元 | 降级 | 买入 → 持有 |
09/30/2021 | 1139.77% | Stifel | → 106 美元 | 启动覆盖范围开启 | → 购买 |
04/06/2021 | 1022.81% | 瑞银(UBS) | → 96 美元 | 启动覆盖范围开启 | → 购买 |
02/11/2021 | 1046.2% | 瑞士信贷 | 62 美元 → 98 美元 | 维持 | 跑赢大盘 |
2021 年 10 月 2 日 | 1069.59% | HC Wainwright & Co. | → 100 美元 | 启动覆盖范围开启 | → 购买 |
08/11/2020 | 648.54% | 坎托·菲茨杰拉德 | → 64 美元 | 启动覆盖范围开启 | → 超重 |
08/11/2020 | 543.27% | 派珀·桑德勒 | → 55 美元 | 启动覆盖范围开启 | → 超重 |
08/11/2020 | 484.8% | 杰富瑞集团 | → 50 美元 | 启动覆盖范围开启 | → 购买 |
08/11/2020 | 519.88% | 瑞士信贷 | → 53 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
What is the target price for ALX Oncology Holdings (ALXO)?
ALX Oncology Holdings(ALXO)的目标价格是多少?
The latest price target for ALX Oncology Holdings (NASDAQ: ALXO) was reported by Stifel on November 14, 2023. The analyst firm set a price target for $10.00 expecting ALXO to rise to within 12 months (a possible 16.96% upside). 16 analyst firms have reported ratings in the last year.
Stifel于2023年11月14日公布了ALX肿瘤控股公司(纳斯达克股票代码:ALXO)的最新目标股价。该分析公司将目标股价定为10.00美元,预计ALXO将在12个月内升至12个月内(可能上涨16.96%)。去年有16家分析公司公布了评级。
What is the most recent analyst rating for ALX Oncology Holdings (ALXO)?
ALX Oncology Holdings(ALXO)的最新分析师评级是多少?
The latest analyst rating for ALX Oncology Holdings (NASDAQ: ALXO) was provided by Stifel, and ALX Oncology Holdings maintained their buy rating.
Stifel对ALX Oncology Holdings(纳斯达克股票代码:ALXO)的最新分析师评级由Stifel提供,ALX Oncology Holdings维持买入评级。
When is the next analyst rating going to be posted or updated for ALX Oncology Holdings (ALXO)?
ALX Oncology Holdings(ALXO)的下一份分析师评级何时公布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ALX Oncology Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ALX Oncology Holdings was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与ALX Oncology Holdings的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月进行一次评级,因此每家公司每年应获得4个评级。ALX Oncology Holdings的最后一次评级是在2023年11月14日提交的,因此您应该预计下一个评级将在2024年11月14日左右公布。
Is the Analyst Rating ALX Oncology Holdings (ALXO) correct?
分析师对ALX Oncology Holdings(ALXO)的评级正确吗?
While ratings are subjective and will change, the latest ALX Oncology Holdings (ALXO) rating was a maintained with a price target of $11.00 to $10.00. The current price ALX Oncology Holdings (ALXO) is trading at is $8.55, which is out of the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但最新的ALX肿瘤学控股公司(ALXO)评级保持不变,目标股价为11.00美元至10.00美元。ALX Oncology Holdings(ALXO)目前的交易价格为8.55美元,超出了分析师的预期区间。